Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1
Authors
Keywords
-
Journal
eLife
Volume 6, Issue -, Pages -
Publisher
eLife Sciences Organisation, Ltd.
Online
2017-06-06
DOI
10.7554/elife.25541
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rapid Optimization of Mcl-1 Inhibitors using Stapled Peptide Libraries Including Non-Natural Side Chains
- (2016) Raheleh Rezaei Araghi et al. ACS Chemical Biology
- hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents
- (2016) Elisa Barile et al. ACS Chemical Biology
- iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry
- (2016) Jeremy Ryan et al. BIOLOGICAL CHEMISTRY
- Designing helical peptide inhibitors of protein–protein interactions
- (2016) Raheleh Rezaei Araghi et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
- (2016) András Kotschy et al. NATURE
- Biophysical determinants for cellular uptake of hydrocarbon-stapled peptide helices
- (2016) Gregory H Bird et al. Nature Chemical Biology
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hierarchy and extremes in selections from pools of randomized proteins
- (2016) Sébastien Boyer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Electrophilic Helical Peptides That Bond Covalently, Irreversibly, and Selectively in a Protein–Protein Interaction Site
- (2016) Aline Dantas de Araujo et al. ACS Medicinal Chemistry Letters
- Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines
- (2016) Brian Koss et al. Oncotarget
- Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer
- (2016) Stephanie Berger et al. eLife
- Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
- (2015) Joan Montero et al. CELL
- Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members
- (2015) Joseph T. Opferman FEBS Journal
- Role of the pro-survival molecule Bfl-1 in melanoma
- (2015) C.K. Hind et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Potent and Specific Peptide Inhibitors of Human Pro-Survival Protein Bcl-x L
- (2015) Sanjib Dutta et al. JOURNAL OF MOLECULAR BIOLOGY
- Locating Herpesvirus Bcl-2 Homologs in the Specificity Landscape of Anti-Apoptotic Bcl-2 Proteins
- (2015) Glenna Wink Foight et al. JOURNAL OF MOLECULAR BIOLOGY
- Designed BH3 Peptides with High Affinity and Specificity for Targeting Mcl-1 in Cells
- (2014) Glenna Wink Foight et al. ACS Chemical Biology
- Genome-Wide Prediction and Validation of Peptides That Bind Human Prosurvival Bcl-2 Proteins
- (2014) Joe DeBartolo et al. PLoS Computational Biology
- Peptide Ligands for Pro-survival Protein Bfl-1 from Computationally Guided Library Screening
- (2013) Sanjib Dutta et al. ACS Chemical Biology
- Multimodal Interaction with BCL-2 Family Proteins Underlies the Proapoptotic Activity of PUMA BH3
- (2013) Amanda L. Edwards et al. CHEMISTRY & BIOLOGY
- Evaluation of the BH3-only Protein Puma as a Direct Bak Activator
- (2013) Haiming Dai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- BH3 profiling in whole cells by fluorimeter or FACS
- (2013) Jeremy Ryan et al. METHODS
- Structure-guided design of a selective BCL-XL inhibitor
- (2013) Guillaume Lessene et al. Nature Chemical Biology
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- BCL2A1is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition
- (2013) Rizwan Haq et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- In Silico and in Vitro Elucidation of BH3 Binding Specificity toward Bcl-2
- (2012) Nir London et al. BIOCHEMISTRY
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Predictive Bcl-2 Family Binding Models Rooted in Experiment or Structure
- (2012) Joe DeBartolo et al. JOURNAL OF MOLECULAR BIOLOGY
- Structure-Based Redesign of the Binding Specificity of Anti-Apoptotic Bcl-xL
- (2012) T. Scott Chen et al. JOURNAL OF MOLECULAR BIOLOGY
- Selective Induction of Cell Death in Melanoma Cell Lines through Targeting of Mcl-1 and A1
- (2012) Daniela Senft et al. PLoS One
- Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets
- (2011) S. M. Schoenwaelder et al. BLOOD
- Mutation to Bax beyond the BH3 Domain Disrupts Interactions with Pro-survival Proteins and Promotes Apoptosis
- (2011) Peter E. Czabotar et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
- (2011) T. N. Chonghaile et al. SCIENCE
- Features and development ofCoot
- (2010) P. Emsley et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- PHENIX: a comprehensive Python-based system for macromolecular structure solution
- (2010) Paul D. Adams et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Inhibition of Bfl-1 with N-aryl maleimides
- (2010) John R. Cashman et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma
- (2010) G. Fan et al. BLOOD
- Determinants of BH3 Binding Specificity for Mcl-1 versus Bcl-xL
- (2010) Sanjib Dutta et al. JOURNAL OF MOLECULAR BIOLOGY
- Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes
- (2010) J. A. Ryan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mcl-1-Bim complexes accommodate surprising point mutations via minor structural changes
- (2010) Emiko Fire et al. PROTEIN SCIENCE
- Conformational Changes in Bcl-2 Pro-survival Proteins Determine Their Capacity to Bind Ligands
- (2009) Erinna F. Lee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- DNA fingerprinting of the NCI-60 cell line panel
- (2009) P. L. Lorenzi et al. MOLECULAR CANCER THERAPEUTICS
- MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family
- (2009) L J Beverly et al. ONCOGENE
- Completing the family portrait of the anti-apoptotic Bcl-2 proteins: Crystal structure of human Bfl-1 in complex with Bim
- (2008) Maria Dolores Herman et al. FEBS LETTERS
- Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins
- (2008) Dayong Zhai et al. MOLECULAR CANCER THERAPEUTICS
- Hydrophile scanning as a complement to alanine scanning for exploring and manipulating protein-protein recognition: Application to the Bim BH3 domain
- (2008) Melissa D. Boersma et al. PROTEIN SCIENCE
- Structural Plasticity Underpins Promiscuous Binding of the Prosurvival Protein A1
- (2008) Callum Smits et al. STRUCTURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started